Transverse Medical Inc. (TMI) is developing the POINT-GUARD™ Dynamic Cerebral Embolic Protection (CEP) medical device to address the devastating and costly problem of stroke during the large and growing number of heart valve procedures that occur annually around the world, such as Transcatheter Aortic Valve Replacement (TAVR).
POINT-GUARD™ is a highly differentiated and proprietary medical device designed to more effectively provide maximum filter coverage to protect the brain, minimize embolic particles from the cerebral flow, and minimize the risk of stroke.
*POINT-GUARD™ is not cleared for sale by any regulatory authority.
Company’s Keywords:
cerebral embolic protection, transcatheter aortic valve, surgical aortic valve, medical device development
<5
<1000000
<2011